Log in
0 followers
Facile Therapeutics is bringing Ebselen into the clinic to demonstrate it will be effective in preventing the recurrence of CDI in a Proof-of-Concept (PoC) clinical trial.
Industries
Headquarters
Stage
Employees
Links
Marc Navre
9 members
3 members
2 members
1 members
BioMarin Pharmaceutical
22 followers
Adaptive Biotechnologies
11 followers
Agilent Technologies
60 followers
Regeneron
77 followers
Verve Therapeutics
53 followers
Discover companies